Skip to main content
. Author manuscript; available in PMC: 2024 Jun 20.
Published in final edited form as: N Engl J Med. 2023 Oct 21;389(24):2256–2266. doi: 10.1056/NEJMoa2304753

Figure 1. Kaplan–Meier Estimates of Overall Survival and Progression-free Survival in the Intention-to-Treat Population.

Figure 1.

Patients in the control group received the investigator’s choice of single-agent therapy with pembrolizumab, ipilimumab, or dacarbazine. Tick marks indicate censored data.